KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Other Non Operating Income (2016 - 2025)

Nektar Therapeutics (NKTR) has 16 years of Other Non Operating Income data on record, last reported at -$121000.0 in Q3 2025.

  • For Q3 2025, Other Non Operating Income fell 0.83% year-over-year to -$121000.0; the TTM value through Sep 2025 reached $270000.0, up 104.15%, while the annual FY2024 figure was -$390000.0, 93.76% up from the prior year.
  • Other Non Operating Income reached -$121000.0 in Q3 2025 per NKTR's latest filing, down from $260000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $5.6 million in Q2 2023 and bottomed at -$6.2 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is $69388.9, with a median of -$67500.0 recorded in 2024.
  • Peak YoY movement for Other Non Operating Income: surged 1464.89% in 2022, then plummeted 176.2% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at -$383000.0 in 2021, then surged by 635.25% to $2.0 million in 2022, then crashed by 404.73% to -$6.2 million in 2023, then skyrocketed by 97.84% to -$135000.0 in 2024, then increased by 10.37% to -$121000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$121000.0 in Q3 2025, $260000.0 in Q2 2025, and $266000.0 in Q1 2025.